Local 12: Study: Targeted drug therapy slows progression of certain brain tumors
Drug could reduce the need for chemotherapy, radiation and surgery, UC expert says
New research out of the University of Cincinnati shows a targeted drug therapy had positive results in delaying the progression of a specific form of glioma, which is a slow-growing brain tumor.
UC Cancer Center brain tumor specialists said it appears to be an option for treatment and would delay radiation and chemotherapy. Local 12 interviewed Rekha Chaudhary, MD, of the Department of Internal Medicine at the UC College of Medicine who said this drug is given after surgery to remove this kind of tumor and appears to be a powerful player in reducing new growth.
Rekha Chaudhary, MD, of the Department of Internal Medicine at the UC College of Medicine/Photo/Colleen Kelley/UC Marketing + Brand
"This new drug Vorasidenib is an IDH1, IDH2 inhibitor. And what it does, it actually inhibits these receptors that are found, or proteins that are found on the tumors,” Chaudhary said.
Researchers studied 331 people with this disease and compared the study drug to a placebo. Those given the targeted therapy did not have disease progression for more than 27.7 months. For those in the placebo group, it was only 11.1 months.
"Whether this is going to pan out to be a survival benefit in the long run, we don't know. But imagine being 30 years old and not having to go through chemo, radiation, further surgery and just be on this drug for almost three years now, and hopefully longer, is a great benefit to these patients, where we've never had a victory before,” Chaudhary told Local 12.
This targeted treatment was so effective that the patients in the original placebo group whose cancer progressed during the study were switched to the drug. It gives promising new hope.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
Colorado silica dust trial could change the way industry does business
May 17, 2026
Betsy Malloy, Andrew Katsanis Professor of Law, at the University of Cincinnati, spoke with Bloomberg Law about how a Colorado trial could change the way the stone fabrication industry does business.
Driven by curiosity, guided by care
May 14, 2026
Max Wilson, a University of Cincinnati College of Allied Health Sciences health sciences major on the pre-physician assistant track, found his path expanding beyond the classroom and into hands-on research focused on human performance and patient care.
New cohort of nursing students get ready to join co-ops
May 14, 2026
A new chapter is beginning for more than 100 University of Cincinnati College of Nursing rising seniors as they embark on one of the most distinctive experiences in undergraduate nursing education: the UC Nursing Co-op Program. The incoming cohort will fan out across Cincinnati's premier healthcare institutions, stepping into some of the most dynamic and specialized clinical environments in the region. Placement sites include UC Medical Center (UCMC), West Chester Hospital, Cincinnati Children's Hospital Medical Center (CCHMC) Burnet, College Hill, and Liberty campus.